Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the sales split between Qbrexza® and Journey Medical’s other dermatology brands or tracking sudden FDA updates can mean combing through hundreds of pages. Stock Titan eases that burden by turning every Journey Medical SEC filings explained simply—from 10-Ks to 8-Ks—into clear, searchable insights.
Our AI engine delivers plain-English briefs moments after each document posts to EDGAR. Need Journey Medical insider trading Form 4 transactions? Real-time alerts show every Journey Medical executive stock transactions Form 4 the minute management buys or sells. Wondering about a Journey Medical quarterly earnings report 10-Q filing? Side-by-side comparisons reveal how R&D spend or licensing fees shift over time.
- Read a Journey Medical annual report 10-K simplified in minutes, not hours.
- Follow each Journey Medical 8-K material events explained—ideal when clinical or regulatory news hits.
- See compensation details fast with the latest Journey Medical proxy statement executive compensation.
- Export the complete Journey Medical Form 4 insider transactions real-time feed for custom models.
- Dive into Journey Medical earnings report filing analysis for trend visualization.
Because revenue hinges on just a few dermatology therapies, even modest disclosure changes can move DERM’s price. Stock Titan’s expert analysis flags those high-impact items first, saving professionals hours and helping them act with confidence.
If you’re searching for “understanding Journey Medical SEC documents with AI,” you’re in the right place. Stop wrestling with legal jargon—our AI-powered summaries, real-time filing updates, and comprehensive coverage make critical information immediately usable.
Journey Medical Corporation (DERM) filed a Form 4 reporting that director Miranda Jayne Toledano received an equity award on 25 June 2025.
- Grant: 7,173 restricted stock units (RSUs) under the 2015 Stock Plan at a grant price of $0.
- Vesting: The RSUs will vest in full on 25 June 2026.
- Post-grant ownership: Toledano now beneficially owns 88,618 Journey Medical common shares, including unvested RSUs, all held directly.
No shares were sold or otherwise disposed of, and no derivative securities were involved. The filing, signed by attorney-in-fact Ramsey Alloush on 07 July 2025, represents a routine director compensation event rather than an open-market transaction.
Journey Medical Corp. (DERM) – Form 4 insider transaction
On June 25 2025, Director Dr. Lindsay A. Rosenwald received 7,173 restricted stock units (RSUs) at a cost of $0 under the company’s 2015 Stock Plan. The RSUs will vest in full on June 25 2026.
After this grant, Dr. Rosenwald beneficially owns 161,146 shares directly and 176,470 shares indirectly through a limited-liability company of which she is the managing member—an aggregate of 337,616 common shares. No shares were sold, and no derivative securities were involved.
The filing reflects routine equity compensation intended to align the director’s interests with shareholders. The grant size is modest relative to typical daily trading volume and does not materially affect the company’s share count or control structure.
Journey Medical Corp (DERM) – Form 4 insider filing: Director Michael Cooper Pearce was granted 7,173 restricted stock units (RSUs) on 25 Jun 2025 under the company’s 2015 Stock Plan. The award was issued at no cost and will vest in full on 25 Jun 2026. After the grant, Pearce’s direct beneficial ownership rose to 37,173 shares, which includes previously awarded RSUs that vest over various schedules. No open-market purchases or sales occurred, and there was no cash consideration. The transaction is routine equity compensation intended to align the director’s interests with shareholders, with only immaterial dilution to existing holders.
Journey Medical (NASDAQ:DERM) filed an 8-K detailing the June 24, 2025 annual meeting results and a Fourth Amended & Restated Certificate of Incorporation. Stockholders owning 85.0% of voting power approved three items:
- Election of six directors for one-year terms
- Ratification of KPMG LLP as 2025 auditor (32,468,451 for; 10,433 against)
- Adoption of the amended charter, which now exculpates corporate officers from certain personal liability
Total votes for the charter change were 25,373,988 for and 798,994 against, with 10,387 abstentions and 6,319,771 broker non-votes. The filing is effective upon Delaware acceptance and is furnished as Exhibit 3.1.
FAQ
What is the current stock price of Journey Medical (DERM)?
What is the market cap of Journey Medical (DERM)?
